SELECT examined the long-term cardiovascular outcomes of patients with pre-existing cardiovascular disease given 2.4 mg semaglutide (Wegovy) over a mean follow-up of 3 years and 4 months. The trial met its primary endpoint, reducing major adverse cardiovascular events (MACE; a composite comprised of, non-fatal myocardial infarction, non-fatal stroke and cardiovascular death) by 20%. The number needed to treat in order to prevent one MACE was 67 – very close to Airfinity’s prediction of 63 in August.

Airfinity’s projections indicate that with moderate coverage, deaths among eligible patients in the US could be reduced by 11% and new onset type 2 diabetes by 43%. With high coverage, deaths could be reduced by 15%, and type 2 diabetes cases by almost two thirds in the same patient population. To discuss access Airfinity's scenario-based forecasting models and the implications these have for the wider cardiometabolic landscape, get in touch here.